<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697304</url>
  </required_header>
  <id_info>
    <org_study_id>1381-0009</org_study_id>
    <secondary_id>2018-002344-81</secondary_id>
    <nct_id>NCT03697304</nct_id>
  </id_info>
  <brief_title>Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.</brief_title>
  <official_title>An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy of BI 754091 in combination with other
      checkpoint inhibitors or anticancer medications in diverse tumour type cohorts.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Due to the current COVID-19 pandemic, the recruitment of new subjects is temporarily
    discontinued. Ongoing, randomised patients are managed per Trial Protocol.
  </why_stopped>
  <start_date type="Actual">March 7, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the trial is objective response (OR), defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Investigator</measure>
    <time_frame>Up to 32 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR), defined as the time from first documented CR or PR (RECIST v1.1) until the earlier of disease progression or death among patients with OR</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control (DC), defined as best overall response of CR, PR, or stable disease (SD) according to RECIST v1.1 as assessed by the Investigator</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS), defined as the time from first treatment until PD or death from any cause, whichever occurs earlier</measure>
    <time_frame>Up to 32 months</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Module A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Module A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Module A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 - Module C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754091</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Cohort 1 - Module A</arm_group_label>
    <arm_group_label>Cohort 1 - Module C</arm_group_label>
    <arm_group_label>Cohort 2 - Module A</arm_group_label>
    <arm_group_label>Cohort 2 - Module C</arm_group_label>
    <arm_group_label>Cohort 3 - Module A</arm_group_label>
    <arm_group_label>Cohort 3 - Module C</arm_group_label>
    <arm_group_label>Cohort 4 - Module C</arm_group_label>
    <arm_group_label>Cohort 5 - Module C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754111</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Cohort 1 - Module A</arm_group_label>
    <arm_group_label>Cohort 2 - Module A</arm_group_label>
    <arm_group_label>Cohort 3 - Module A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836880</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Cohort 1 - Module C</arm_group_label>
    <arm_group_label>Cohort 2 - Module C</arm_group_label>
    <arm_group_label>Cohort 3 - Module C</arm_group_label>
    <arm_group_label>Cohort 4 - Module C</arm_group_label>
    <arm_group_label>Cohort 5 - Module C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Master Protocol:

          -  Provision of signed and dated, written Master informed consent form (ICF) prior to any
             trial-specific procedures, sampling, or analyses.

          -  Patient ≥18 years of age at the time of signature of the ICF.

          -  Eastern Cooperative Oncology Group (ECOG) score: 0 to 1.

          -  Patient must agree to a pre-treatment biopsy (if archival tissue is not available) and
             on-treatment tumour biopsy.

          -  Life expectancy of at least 12 weeks after the start of the treatment according to the
             Investigator's judgement.

          -  Male or female patients. Women of childbearing potential (WOCBP) and men able to
             father a child must be willing and able to use highly effective methods of birth
             control (that result in a low failure rate of less than 1% per year when used
             consistently and correctly) during trial participation and for at least 6 months after
             the last administration of trial medication.

        Module A:

        - Histologically confirmed diagnosis of one of the following cohorts:

          -  Cohort 1 GEC - Locally advanced, unresectable or metastatic gastric adenocarcinoma or
             gastro oesophageal adenocarcinoma (GEC) (defined as primary tumour localisation below
             the gastro oesophageal junction (GEJ) with prior anti-PD-1 or anti-PD-L1 based treated
             tumour.

          -  Cohort 2 Patients with secondary resistance to anti-PD-1 or anti-PD-L1 based therapy:
             Any advanced or metastatic solid tumour with previously anti-PD-1 or anti-PD-L1 based
             treatment who progressed after achieving benefit

          -  Cohort 3 Patients with primary resistance to anti-PD-1 or anti-PD-L1 based therapy:
             Select advanced or metastatic solid tumour types with previous anti-PD- 1/PD-L1 based
             treated tumour without achieving benefit.

          -  All patients must have measurable lesions according to RECIST v1.1

          -  Patient must agree to pre- and on-treatment tumour biopsies. If archived tumour tissue
             is available from the last treatment failure, sections may be supplied instead of a
             pre-treatment biopsy.

        Module C:

          -  Histologically confirmed diagnosis of one of the following cohorts:

               -  Cohort 1: GEC: Locally advanced, unresectable or metastatic gastric
                  adenocarcinoma or GEC.

               -  Cohort 2: Patients with secondary resistance to anti-PD-1 or anti-PD-L1 based
                  therapy: Any advanced or metastatic solid tumour (excluding NSCLC and melanoma)
                  with previously anti-PD-1 or anti-PD-L1 based treatment which progressed after
                  achieving benefit.

               -  Cohort 3: Patients with primary resistance to anti-PD-1 or anti-PD-L1 based
                  therapy: Select advanced or metastatic solid tumour types with previous
                  anti-PD-1/PD-L1 based treated tumour without achieving benefit.

               -  Cohort 4: Locally advanced, unresectable or metastatic second line or greater,
                  microsatellite stable (MSS) colorectal cancer.

               -  Cohort 5: Advanced Endometrial cancer: Endometrial carcinoma that is pMMR
                  (Mismatch Repair-Proficient)/MSS and is advanced, recurrent, or persistent and
                  has relapsed or is refractory to curative therapy.

          -  All patients must have at least one measurable lesion according to RECIST v1.1

          -  Further inclusion criteria apply

        Exclusion Criteria

        Master Protocol:

          -  Any investigational treatment anti-tumour treatment within 4 weeks or within 5
             half-life periods (whichever is shorter) prior to the initiation of trial treatment.

          -  More than one anti-PD-(L)1-based treatment regimen prior to entering study

          -  Major surgery ('major' according to the Investigator's assessment) performed within 12
             weeks prior to first trial treatment or planned within 12 months after screening,
             e.g., hip replacement.

          -  Known history of severe hypersensitivity reactions to other mAbs or known
             hypersensitivity to the trial drugs or their excipients.

          -  Known presence of symptomatic central nervous system (CNS) metastases, unless
             asymptomatic and off corticosteroids and/or anticonvulsant therapy for at least 2
             weeks prior to start of treatment.

          -  Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within
             4 weeks prior to the first dose of study treatment.

          -  Active autoimmune disease or a documented history of autoimmune disease, except
             vitiligo or resolved childhood asthma/atopy. Patients who were permanently
             discontinued from previous anti-PD-1 or anti-PD-L1 therapy because of a immune-related
             adverse event (irAE).

        Module A:

        - Previous treatment with an anti-LAG-3 Agent

        Module C:

          -  Persistent toxicity from previous treatments that has not resolved to ≤Grade 1 with
             the exception of alopecia

          -  Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension,
             unstable angina, history of infarction within past 6 months, congestive heart failure
             &gt; New York Heart Association [NYHA] II)

          -  History of severe haemorrhagic or thromboembolic event in the past 12 months

          -  Known inherited predisposition to bleeding or to thrombosis, in the opinion of the
             investigator - Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - East</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University School of Community Medicine</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College Of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute (University of Alberta)</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
Studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
Studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to:
find information in order to request access to clinical study data, for listed studies.
request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

